Avenue Therapeutics (ATXI) Misses Q1 EPS by 640c

Avenue Therapeutics (NASDAQ: ATXI) reported Q1 EPS of ($15.40), $6.40 worse than the analyst estimate of ($9.00).

For earnings history and earnings-related data on Avenue Therapeutics (ATXI) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Anthropic delays planned IPO from October to November - WSJ
• Arrive AI and DXC Technology partner to bring delivery tech to factories